TheraRadar
← Back
Data updated: Jun 28, 2026

PARAGON BIOTECK

Pharma
Pharmaceuticals

PARAGON BIOTECK is a pharmaceutical company with 1 FDA-approved products.

2013
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

PARAGON BIOTECK's Key Drugs

PARAGON BIOTECK's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PARAGON BIOTECK's Recent FDA Approvals

New NDA/BLA approvals for PARAGON BIOTECK over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PARAGON BIOTECK's Therapeutic Areas

Disease areas where PARAGON BIOTECK has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

PARAGON BIOTECK Pipeline Snapshot

Active clinical trials for PARAGON BIOTECK across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling